Literature DB >> 12107251

Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients.

Andrea F Attanasio1, Simon Howell, Peter C Bates, Paul Frewer, John Chipman, Werner F Blum, Stephen M Shalet.   

Abstract

If GH therapy of children with GH deficiency (GHD) has been adequate, body composition should be comparable to that of patients who have undergone normal childhood development and become hypopituitary thereafter. To assess this, body composition was determined in 92 patients with childhood onset (CO) GHD, aged 18-30 yr, who had been treated to final height with GH for 8.98 +/- 4.30 yr and had stopped treatment 1.57 +/- 1.20 yr previously, but who remained GHD (assessed by a GH stimulation test and IGF-I values). These were compared with 35 age-matched GH-naïve hypopituitary patients with adult onset (AO) GHD. Lean body mass, fat mass, and total bone mineral content were assessed by dual energy x-ray absorptiometry and corrected for actual height. CO patients were shorter (CO height, -1.18 +/- 1.16 SD score; AO height, -0.38 +/- 1.12 SD score; P < 0.001) and had lower body mass index (CO, 23.19 +/- 5.76 kg/m(2); AO, 28.9 +/- 6.27 kg/m(2); P < 0.001) than the AO group. Although there were gender differences, within genders CO patients had lower lean body mass, fat mass, and bone mineral content (P < 0.001 in all cases) compared with AO patients. Standard deviation scores for IGF-I (CO female, -9.2 +/- 3.1; AO female, -5.2 +/- 2.6; CO male, -6.4 +/- 2.7; AO male, -3.5 +/- 2.3; P < 0.001 within each gender) and IGFBP-3 (CO female, -3.5 +/- 2.5; AO female, -1.7 +/- 1.5; CO male, -2.8 +/- 2.0; AO male, -1.1 +/- 1.6; P < 0.001 within each gender) were significantly lower in the CO group. These results suggest that patients with CO GHD who were treated to final height suffer a significant maturational deficit despite GH replacement during childhood.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12107251     DOI: 10.1210/jcem.87.7.8593

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Growth hormone treatment of adolescents with growth hormone deficiency (GHD) during the transition period: results of a survey among adult and paediatric endocrinologists from Italy. Endorsed by SIEDP/ISPED, AME, SIE, SIMA.

Authors:  G Aimaretti; R Attanasio; S Cannavò; M C Nicoletti; R Castello; C Di Somma; P Garofalo; L Iughetti; S Loche; M Maghnie; L Mazzanti; G Saggese; M Salerno; G Tonini; V Toscano; S Zucchini; M Cappa
Journal:  J Endocrinol Invest       Date:  2014-11-02       Impact factor: 4.256

Review 2.  Growth hormone - past, present and future.

Authors:  Michael B Ranke; Jan M Wit
Journal:  Nat Rev Endocrinol       Date:  2018-03-16       Impact factor: 43.330

Review 3.  [Congenital adrenal hyperplasia and growth hormone deficiency. Special care in transition to adulthood].

Authors:  H G Dörr; C Schöfl
Journal:  Internist (Berl)       Date:  2009-10       Impact factor: 0.743

Review 4.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

5.  MULTIFACETED EVALUATION OF 72 PATIENTS WITH PITUITARY FAILURE.

Authors:  H Düğeroğlu; A Karakaş
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Oct-Dec       Impact factor: 0.877

6.  United States multicenter study of factors predicting the persistence of GH deficiency during the transition period between childhood and adulthood.

Authors:  Charmian A Quigley; Anthony J Zagar; Charlie Chunhua Liu; David M Brown; Carol Huseman; Lynne Levitsky; David R Repaske; Eva Tsalikian; John J Chipman
Journal:  Int J Pediatr Endocrinol       Date:  2013-02-13

7.  Increased height standard deviation scores in response to growth hormone therapy to near-adult height in older children with delayed skeletal maturation: results from the ANSWER Program.

Authors:  Judith L Ross; Peter A Lee; Robert Gut; John Germak
Journal:  Int J Pediatr Endocrinol       Date:  2015-01-15

8.  The Challenge of Growth Hormone Deficiency Diagnosis and Treatment during the Transition from Puberty into Adulthood.

Authors:  Elena Inzaghi; Stefano Cianfarani
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-20       Impact factor: 5.555

Review 9.  IGF-I measurements in the diagnosis of adult growth hormone deficiency.

Authors:  Anita Y M Kwan; Mark L Hartman
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

10.  Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency.

Authors:  J M Garcia; R Swerdloff; C Wang; M Kyle; M Kipnes; B M K Biller; D Cook; K C J Yuen; V Bonert; A Dobs; M E Molitch; G R Merriam
Journal:  J Clin Endocrinol Metab       Date:  2013-04-04       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.